SCHEMBL1852235

SCHEMBL1852235

Cc1c(Cc2cccc(C(F)(F)F)c2)sc2c(-c3cccc(C(N)=O)c3)cccc12

nearest known ligand 0.54

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 17/20 0.54
MAOB P27338 1/20 0.42
BACE1 P56817 1/20 0.40
SLC9A1 P19634 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1850602 0.92 GPR52 (0.49) GPR52BACE1
SCHEMBL1850978 0.90 GPR52 (0.49) GPR52
SCHEMBL3198309 0.90 GPR52 (0.48) GPR52MAOBBACE1
SCHEMBL1847725 0.89 GPR52 (0.70) GPR52BACE1
SCHEMBL3217369 0.87 GPR52 (0.50) GPR52MAOB
SCHEMBL1852205 0.86 GPR52 (0.47) GPR52
SCHEMBL1849415 0.86 GPR52 (0.69) GPR52
SCHEMBL1852456 0.86 GPR52 (0.46) GPR52MAOB
SCHEMBL3211211 0.85 GPR52 (0.71) GPR52
SCHEMBL1853064 0.84 KDM4C (0.48) GPR52MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885MAOB 1106/4885BACE1 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.